Multi-kinase inhibitors including sorafenib and lenvatinib were the first-line systemic treatment options for unresectable hepatocellular carcinoma (uHCC) patients, albeit with a median overall survival (OS) of around 1 year.¹ Following the regulatory approval based on the significant OS improvement in 2020, atezolizumab + bevacizumab (atezo/bev) became a new and current standard of care (SoC) for uHCC.¹ Despite the tremendous advancement, additional systemic treatment options with long-term efficacy and well tolerated safety profiles are still warranted to cater for individual medical needs of uHCC patients.² Very recently, a novel immunotherapy (IO) combination (i.e., the STRIDE regimen) featuring a single high-priming dose of tremelimumab (TREME) [an anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)] and every-4-week durvalumab (DUR) (anti-PD-L1) showed encouraging clinical efficacy and high tolerability in a phase 3 trial, becoming the latest addition to the armamentarium of first-line systemic treatment options for uHCC patients.² In the 4^th AGM and HBP workshop organized by the Hong Kong Stereotactic Body Radiation Therapy (SBRT) Study Group, Professor Arndt Vogel and Dr. Chiang, Chi-Leung presented new data and discussed the latest advancement in the rapidly evolving treatment landscape of uHCC. Subsequently in an interview with Omnihealth Practice, Dr. Chiang shared his insights into the new dual IO treatment option in uHCC. He also provided updates on the ongoing study START-FIT [transarterial chemoembolization (TACE) + SBRT + dual IO] with promising early results. At the end of the interview, he shared a clinical case which demonstrated the remarkable efficacy of SBRT + dual IO in a local uHCC patient

In 2016, a young woman in her 20s complained of sudden abdominal pain in the morning which then deteriorated rapidly, and was subsequently admitted to the intensive care unit (ICU) of Prince of Wales Hospital (PWH). The patient was diagnosed with Crohn’s disease (CD). During her ICU stay, the patient underwent 2 major surgical procedures and received massive blood transfusion due to her severe intestinal bleeding. The patient had been staying in the ICU for 3 months and was discharged from PWH only about 3 years later. This case reminds us of the considerable suffering of the CD patients and the immense challenges of overall disease management. Considering its rising prevalence in Hong Kong, CD is set to increase the medical needs of patients and the disease burden of the society.¹ In an interview with Omnihealth Practice, Dr. Lam, Long-Yan Kelvin talked about the latest advances in CD management and the ongoing difficulties in local clinical practice.